Chongfan Technology
News
24
2024
-
09
A review of the mechanism and treatment progress of glucagon-like peptide -1 receptor published by Gao Junjie team of Shanghai Jiaotong University
Author:
The glucagon-like peptide -1 (GLP-1) receptor, known as GLP-1R, is an important part of the G protein-coupled receptor (GPCR) family, which is mainly found on the surface of various cells in the human body. This receptor specifically interacts with GLP-1, and GLP-1 is a key hormone that plays an integral role in regulating blood sugar levels, lipid metabolism, and a number of other important biological functions.
On September 18, 2024, the Gao Junjie team of Shanghai Jiaotong UniversitySignal Transduction and Targeted TherapyPublished online entitled“Glucagon-like peptide-1 receptor: mechanisms and advances in therapy”The summary,The reviewThe development milestones of GLP-1 drugs are comprehensively traced, from initial discovery to clinical application, detailing the evolution of various GLP-1 drugs and their unique pharmacological properties.
In recent years, GLP-1 drugs have become the focus of the medical community because of their innovative therapeutic mechanism, significant efficacy and broad prospects for development. The potential applications of GLP-1 receptor agonists (GLP-1RAs) in neuroprotection, anti-infection, reduction of various types of inflammation, and enhancement of cardiovascular function were also discussed. It provides an in-depth assessment of the effectiveness of GLP-1RAs in multiple body systems, including the nervous, cardiovascular, musculoskeletal, and digestive systems. This includes integrating the latest clinical trial data to delve into underlying signaling pathways and pharmacological mechanisms. The main purpose of the review is to highlight the broad benefits of GLP-1RAs in the treatment of multiple diseases, such as obesity, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer.The continuous development of new indications for GLP-1 drugs offers good prospects for further expansion of therapeutic interventions, demonstrating their great potential in the medical field.
In recent years, GLP-1R and its agonists have attracted wide attention in the medical field. GLP-1R is the core member of the GPCR family, which widely exists on the surface of various human cells.It regulates blood glucose levels and lipid metabolism by specifically binding key hormonal GLP-1. This receptor and its agonists have significant therapeutic potential, reshaping the treatment of a variety of diseases, including diabetes, cardiovascular disease and neurodegenerative diseases. GLP-1 is a peptide produced by the cleavage of proglucagon and is synthesized primarily in intestinal mucosal l-cells, islet α-cells, and neurons in solitary fascicles. GLP-1RAs mimic the role of endogenous GLP-1, activate GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central appetite suppression. These mechanisms make GLP-1RAs a powerful tool for controlling blood sugar and improving metabolic syndrome. In addition, their multifaceted mechanism of action suggests potential applications beyond traditional metabolic disorders. From the discovery of GLP-1 fragment GLP-1 (7-37) to the development of more stable, long-acting GLP-1 analogs, these milestones represent major breakthroughs in the field of medicine. For example, the success of exenatide not only stimulated the development of powerful GLP-1 analogs such as liraglutide and simarlutide, but also revealed the great potential of GLP-1RAs in the treatment of various systemic diseases.These advances underscore the importance of GLP-1RAs in modern treatment. The applications of GLP-1RAs extend far beyond the management of diabetes.
The complex mechanism of GLP-1RAs and its latest progress in the treatment of various diseases are reviewed,Such as musculoskeletal inflammation, obesity, cardiovascular disease, NAFLD, neurodegenerative diseases and various cancers. The review presents recent studies demonstrating the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation and enhancing cardiovascular health. For example, in the treatment of Alzheimer's disease (AD) and Parkinson's disease (PD), GLP-1RAs has shown potential to slow disease progression, while its anti-inflammatory properties offer new hope for diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), and cardiovascular disease. Explore the efficacy of GLP-1RAs in the treatment of neurological, cardiovascular, endocrine and digestive diseases by integrating the latest clinical trial data. The review states that GLP-1RAs have also been found to significantly reduce the risk of heart failure, atherosclerosis (AS) and hypertension, highlighting their broad therapeutic potential. With the continuous development of new indications, GLP-1 drugs show great potential in the medical field, and future research is expected to expand their therapeutic applications.A comprehensive exploration of their benefits underscores their transformative potential in medicine, positions them as a promising approach to a wide range of health problems, and paves the way for new research and clinical applications.
The future of GLP-1RA treatment is promising.Researchers are developing more effective formulations, such as long-acting and oral formulations, to improve patient compliance and outcomes. With increasing clinical evidence, GLP-1RAs will be key to treating complex and chronic diseases, providing significant health benefits, addressing unmet medical needs, thereby improving patients' quality of life, and consolidating its role in future medical advances.
Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control
LATEST NEWS
Thank you for visiting the official website of Chongfan Technology. If you have cooperation intentions or suggestions, please contact us through the following methods, and we will reply as soon as possible, thank you!
Address: Room 403, Building 6, Phase III of R&D, No. 36 Xiyong Avenue, High tech Zone, Chongqing, China.
Telephone: +86-13658337211
E-mail: Sales@cfkeji.net
Website: www.cfkeji.net
Mobile Version
